


Stabilis



Cefuroxime sodium



Tradename

Aksef	Turkey
Anaptivan	Greece
Aprok	Ireland
Aprokam	Belgium, Great Britain, Iceland, Turkey
Axetine	Romania
Biofuroksyn	Poland
Cefofix	Saudi Arabia
Cefurin	Italy
Cefurox	Argentina
Cefuroxim	Germany
Ceruxim	Greece
Curocef	Austria
Curoxim	Italy
Curoxima	Spain
Curoxime	Portugal
Duxima	Italy
Galemin	Greece
Gonif	Greece
Itorex	Italy
Kefurox	Belgium
Keroxime	Brazil
Lafurex	Italy
Maxim	Saudi Arabia
Multisef	Turkey
Nipogalin	Greece
Normafenac	Greece
Plixym	Poland
Prokam	Spain
Receant	Greece
Supero	Italy
Tarsime	Poland
Vekfazolin	Greece
Ximaract	Belgium, Great Britain, Spain
Xorim	Poland
Yokel	Greece
Zetagal	Greece
Zilisten	Greece
Zinacef	Belgium, Brazil, Canada, Denmark, Finland, Germany, Great Britain, Greece, Netherlands, Norway, Poland, Saudi Arabia, Slovenia, Sweden, Switzerland, United States of America

Zinnat	France, Turkey
Zinocep	Italy
Zinoxime	Saudi Arabia



Stability in solutions

		15 mg/ml	25°C		48			644
		5 & 10 mg/ml	-10°C		30			636
		5 & 10 mg/ml	25°C		24			636
		5 & 10 mg/ml	5°C		30			636
		7,5 mg/ml	2-8°C		7			1452
		7,5 mg/ml	25°C		24			1452
		22,5 & 45 mg/ml	3°C		7			443
		30 & 60 mg/ml	-20°C		30			443
		5 & 10 mg/ml	-10°C		30			636
		5 & 10 mg/ml	25°C		24			636
		5 & 10 mg/ml	5°C		30			636
		6 mg/ml	25°C		24			1656
		6 mg/ml	4°C		7			1656
		15 mg/ml	-30°C		90			1958
		15 mg/ml	4°C		11			656
		15 mg/ml	4°C		15			1958
		15 mg/ml	-20°C		98			2008
		15 mg/ml	4°C		31			2095

		7,5 mg/ml	2-8°C		7			1452
		7,5 mg/ml	25°C		24			1452
		10 mg/ml	-18°C		120			3569
		10 mg/ml	-20°C		365			1972
		10 mg/ml	25°C		16			1972
		10 mg/ml	5°C		21			1972
		50 mg/ml	25°C		2			1813
		50 mg/ml	5°C		21			1813
		90 mg/ml	25°C		48			4284
		90 mg/ml	4°C		14			4284
		5 & 30 mg/ml	4°C		10			604
		10 mg/ml	-20°C		365			1972
		10 mg/ml	25°C		16			1972
		10 mg/ml	5°C		21			1972



Stability of mixtures

		7,5 & 15 mg/ml	22°C		Aminophylline : 1 & 2 mg/ml	4		96
		15 mg/ml	25°C		Clindamycin phosphate : 9 mg/ml	48		644
		7,5 & 15 mg/ml	22°C		Theophylline : 0,8 mg/ml	4		96
		7,5 & 15 mg/ml	22°C		Aminophylline : 1 & 2 mg/ml	4		96
		7,5 & 15 mg/ml	22°C		Aminophylline : 1 & 2 mg/ml	4		96
		7,5 mg/ml	4°C		Metronidazole : 5 mg/ml	7		961






















































Factors which affect stability

				4284
				636



Compatibility

			
	Cefuroxime sodium : 15 mg/ml Aciclovir sodium : 5 mg/ml		336
	Cefuroxime sodium : 30 mg/ml Alfentanil hydrochloride : 500 µg/ml		3380
	Cefuroxime sodium : 20 mg/ml Allopurinol sodium : 3 mg/ml		307
	Cefuroxime sodium : 30 mg/ml Amifostine : 10 mg/ml		3
	 Cefuroxime sodium Amikacin sulfate		3549
	 Cefuroxime sodium Amikacin sulfate		3687
	Cefuroxime sodium : 7,5 & 15 mg/ml Aminophylline : 1 & 2 mg/ml		96
	Cefuroxime sodium : 7,5 & 15 mg/ml Aminophylline : 1 & 2 mg/ml		96
	Cefuroxime sodium : 7,5 & 15 mg/ml Aminophylline : 1 & 2 mg/ml		96
	Cefuroxime sodium : 30 mg/ml Amiodarone hydrochloride : 6 mg/ml		1611
	Cefuroxime sodium : 100 mg/ml Amoxicillin sodium / clavulanic acid : 100/10 mg/ml		3824
	Cefuroxime sodium : 30 mg/ml Anidulafungin : 0.5 mg/ml		1982
	Cefuroxime sodium : 7.5 mg/ml Atracurium besylate : 0.5 mg/ml		402
	 Cefuroxime sodium : 100 mg/ml Azithromycine : 2 mg/ml		1800
	Cefuroxime sodium : 30 mg/ml Aztreonam : 40 mg/ml		99
	Cefuroxime sodium : 30 mg/ml Bivalirudin : 5 mg/ml		1713
	Cefuroxime sodium : 100 mg/ml Caffeine : 10 mg/ml		3964
	Cefuroxime sodium : 30 mg/ml Ceftolozane / tazobactam : 10/5 mg/ml		3828
	 Cefuroxime sodium : 30 mg/ml Ciprofloxacin lactate : 2 mg/ml		285
	 Cefuroxime sodium : 30 mg/ml Cisatracurium besylate : 2 & 5 mg/ml		299
	Cefuroxime sodium : 15 mg/ml Clindamycin phosphate : 9 mg/ml		644
	Cefuroxime sodium : 90 mg/ml Cloxacillin sodium : 100 mg/ml		3012
	Cefuroxime sodium Dimenhydrinate		2087
	Cefuroxime sodium : 30 mg/ml Fenoldopam mesylate : 80 µg/ml		1803

		Cefuroxime sodium : 15 mg/ml Fentanyl citrate : 50 µg/ml		63
		Cefuroxime sodium : 30 mg/ml		301
		Cefuroxime sodium : 30 mg/ml Dexmedetomidine : 4 µg/ml		1712
		Cefuroxime sodium : 100 mg/ml Diltiazem hydrochloride : 1 & 5 mg/ml		198
		Cefuroxime sodium : 15 mg/ml Diltiazem hydrochloride : 5 mg/ml		198
		Cefuroxime sodium : 30 mg/ml Docetaxel : 0.9 mg/ml		1754
		Cefuroxime sodium : 30 mg/ml Etoposide phosphate : 5 mg/ml		1410
		Cefuroxime sodium : 30 mg/ml		1415
		Cefuroxime sodium Erythromycin lactobionate		3674
		Cefuroxime sodium : 15 mg/ml Famotidine		397
		Cefuroxime sodium : 20 mg/ml Famotidine : 2 mg/ml		215
		Cefuroxime sodium : 30 mg/ml Fentanyl citrate : 50 µg/ml		3380
		Cefuroxime sodium : 20 mg/ml Filgrastim : 30 µg/ml		244
		Cefuroxime sodium : 37,5 mg/ml Flucloxacillin sodium : 20 mg/ml		1232
		Cefuroxime sodium : 30 mg/ml Fluconazole : 2 mg/ml		496
		Cefuroxime sodium : 30 mg/ml Fosfomycin : 30 mg/ml		4055
		Cefuroxime sodium : 37,5 mg/ml Furosemide : 1 mg/ml		1232
		Cefuroxime sodium : 100 mg/ml	RL	4603
		Cefuroxime sodium : 30 mg/ml Fludarabine phosphate : 1 mg/ml		492
		Cefuroxime sodium : 30 mg/ml Foscarnet sodium : 24 mg/ml		73
		Cefuroxime sodium : 30 mg/ml Gemcitabine hydrochloride : 10 mg/ml		1423
		Cefuroxime sodium Gentamicin sulfate		3687
		Cefuroxime sodium Gentamicin sulfate		3643
		Cefuroxime sodium Gentamicin sulfate		3520
		Cefuroxime sodium : 30 mg/ml Granisetron hydrochloride : 0.05 mg/ml		182
		Cefuroxime sodium Heparin sodium : 10 & 50 UI/ml		3687
		Cefuroxime sodium : 30 mg/ml Hetastarch : 60 mg/ml		1721

		Cefuroxime sodium : 30 mg/ml Hydromorphone hydrochloride : 0.2 mg/ml		405
		Cefuroxime sodium : 30 mg/ml Isavuconazonium sulfate : 1.5 mg/ml		3829
		Cefuroxime sodium Kanamycin sulfate		3687
		Cefuroxime sodium : 100 mg/ml Ketamine hydrochloride : 50 mg/ml		2109
		Cefuroxime sodium Lidocaine hydrochloride : 10 mg/ml		3687
		Cefuroxime sodium : 30 mg/ml Linezolid : 2 mg/ml		1925
		Cefuroxime sodium : 20 mg/ml Melphalan : 0.1 mg/ml		169
		Cefuroxime sodium : 100 mg/ml Meropenem : 50 mg/ml		4319
		Cefuroxime sodium : 7,5 mg/ml Metronidazole : 5 mg/ml		961
		Cefuroxime sodium Metronidazole		3594
		Cefuroxime sodium : 7.5 mg/ml Midazolam hydrochloride : 0.05 >> 0.4 mg/ml		1888
		Cefuroxime sodium : 15 mg/ml Midazolam hydrochloride : 1 mg/ml		176
		Cefuroxime sodium : 30 mg/ml Morphine sulfate : 1 mg/ml		405
		Cefuroxime sodium N-acetylcysteine : 200 mg/ml		3766
		Cefuroxime sodium : 100 mg/ml Naloxone hydrochloride : 0.4 mg/ml		3408
		Cefuroxime sodium Netilmicin sulfate		3687
		Cefuroxime sodium : 30 mg/ml Ondansetron hydrochloride : 1 mg/ml		334
		Cefuroxime sodium : 7.5 mg/ml Pancuronium bromide : 0.05 mg/ml		402
		Cefuroxime sodium Pantoprazole sodium		2090
		Cefuroxime sodium : 100 mg/ml Paracetamol : 10 mg/ml		4742
		Cefuroxime sodium : 30 mg/ml Pemetrexed disodium : 20 mg/ml		1953
		Cefuroxime sodium : 30 mg/ml Pethidine hydrochloride : 10 mg/ml		405
		Cefuroxime sodium : 62,5 mg/ml Phloroglucinol : 2,5 mg/ml		3791
		Cefuroxime sodium : 30 mg/ml Piritramide : 0.5 mg/ml		3380
		Cefuroxime sodium : 30 mg/ml Piritramide : 7.5 mg/ml		3380
		Cefuroxime sodium : 30 mg/ml Plazomicin sulfate : 24 mg/ml		4145

	Cefuroxime sodium Potassium chloride : 10 & 40 mEq/l		3687
	Cefuroxime sodium : 30 mg/ml Propofol : 10 mg/ml		300
	Cefuroxime sodium : 30 mg/ml Remifentanyl hydrochloride : 25 & 250 µg/ml		59
	Cefuroxime sodium : 100 mg/ml Salbutamol sulfate : 1 mg/ml		3216
	Cefuroxime sodium : 30 mg/ml Sargramostim : 10 µg/ml		335
	Cefuroxime sodium Streptomycin sulfate		3687
	Cefuroxime sodium : 30 mg/ml Sufentanil citrate : 0.005 mg/ml		3380
	Cefuroxime sodium : 30 mg/ml Sulbactam/durlobactam : 15/15 mg/ml		4801
	Cefuroxime sodium : 30 mg/ml Tacrolimus : 1000 µg/ml		479
	Cefuroxime sodium : 30 mg/ml Tedizolid phosphate : 0.8 mg/ml		3827
	Cefuroxime sodium : 30 mg/ml Temocilline : 83.33 mg/ml		2231
	Cefuroxime sodium : 20 mg/ml Teniposide : 0.1 mg/ml		905
	Cefuroxime sodium : 7,5 & 15 mg/ml Theophylline : 0,8 mg/ml		96
	Cefuroxime sodium : 100 mg/ml Thiopental sodium : 25 mg/ml		3767
	Cefuroxime sodium : 30 mg/ml Thiotepa : 1 mg/ml		249
	Cefuroxime sodium Tobramycin sulfate		3687
	Cefuroxime sodium : 1 >> 150 mg/ml Vancomycin hydrochloride : 2 mg/ml		1674
	Cefuroxime sodium : 1 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
	Cefuroxime sodium : 10 >> 150 mg/ml Vancomycin hydrochloride : 20 mg/ml		1674
	Cefuroxime sodium : 7.5 mg/ml Vecuronium bromide : 0.1 mg/ml		402
	Cefuroxime sodium : 20 mg/ml Vinorelbine tartrate : 1 mg/ml		84



Route of administration





References

	Type	Publication
3	Journal	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
59	Journal	Trissel LA, Gilbert DL, Martinez JF, Kim MC. Compatibility of remifentanyl hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
63	Journal	Marquardt Ed, Lam SSY. Visual compatibility of fentanyl citrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 811-812.
73	Journal	Lor E, Takagi J. Visual compatibility of foscarnet with other injectable drugs. Am J Hosp Pharm 1990 ; 47: 157-159.
84	Journal	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
96	Journal	Stewart JT, Warren FW, Johnson SM. Stability of cefuroxime sodium and aminophylline or theophylline. Am J Hosp Pharm 1994 ; 51: 809-811.
99	Journal	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169	Journal	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
176	Journal	Mantong ML, Marquardt ED. Visual compatibility of midazolam hydrochloride with selected drugs during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 2567-2568.
182	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 56-60.
198	Journal	Gayed AA, Kheshary PR, Hinkle RL. Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection. Am J Health-Syst Pharm 1995 ; 52: 516-520.
215	Journal	Keyi X, Gagnon N, Bisson C, Desmarais M, LeBel M. Stability of famotidine in polyvinyl chloride minibags and polypropylene syringes and compatibility of famotidine with selected drugs. Ann Pharmacotherapy 1993 ; 27: 422-426.
244	Journal	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	Journal	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
285	Journal	Elmore RL, Contois ME, Kelly J, Noe A, Poirier A. Stability and compatibility of admixtures of intravenous ciprofloxacin and selected drugs. Clin Ther 1996 ; 18: 246-255.

299	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
300	Journal	Trissel LA, Gilbert DL, Martinez JF. Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301	Journal	Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM. Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307	Journal	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	Journal	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
335	Journal	Trissel LA, Bready BB, Kwan JW, Santiago NM. Visual compatibility of sargramostim with selected antineoplastic agents, anti-infectives, or other drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 402-406.
336	Journal	Forman JK, Lachs JR, Souney PF. Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection. Am J Hosp Pharm 1987 ; 44: 1408-1409.
397	Journal	Fong PA, Ward J. Visual compatibility of intravenous famotidine with selected drugs. Am J Hosp Pharm 1989 ; 46: 125-126.
402	Journal	Savitsky ME. Visual compatibility of neuromuscular blocking agents with various injectable drugs during simulated Y-site injection. Am J Hosp Pharm 1990 ; 47: 820-821.
405	Journal	Nieves-Cordero AL, Luciw HM, Souney PF. Compatibility of narcotic analgesic solutions with various antibiotics during simulated Y-site injection. Am J Hosp Pharm 1985 ; 42: 1108-1109.
443	Journal	Stiles ML, Allen LV, Fox JL. Stability of ceftazidime (with arginine) and of cefuroxime sodium in infusion-pump reservoirs. Am J Hosp Pharm 1992 ; 49: 2761-2764.
479	Journal	Min DI, Brown T, HWang GC. Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection. Am J Hosp Pharm 1992 ; 49: 2964-2966.
492	Journal	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
496	Journal	Lor E, Sheybani T, Takagi J. Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration. Am J Hosp Pharm 1991 ; 48: 744-746.
604	Manufacturer	Stabilité des médicaments dans l'Intermate® SV50, 100, 200 Baxter 1998
636	Journal	Das Gupta V, Stewart KR. Stability of cefuroxime sodium in some aqueous buffered solutions and intravenous admixtures. J Clin Hosp Pharm 1986 ; 11: 47-54.


644	Journal	Marble DA, Bosso JA, Townsend RJ. Compatibility of clindamycin phosphate with aztreonam in polypropylene syringes and with cefoperazone sodium, cefonicid sodium, and cefuroxime sodium in partial-fill glass bottles. Drug Intell Clin Pharm 1988 ; 22: 54-57.
656	Journal	Galanti LM, Hecq JD, Vanbeckbergen D, Jamart J. Long-term stability of cefuroxime and cefazolin sodium in intravenous infusions. J Clin Pharm Ther 1996 ; 21: 185-189.
905	Journal	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
961	Journal	Barnes AR. Chemical stabilities of cefuroxime sodium and metronidazole in an admixture for intravenous infusion. J Clin Pharm Ther 1990 ; 15: 187-196.
1232	Journal	Beatson C, Taylor A. A physical compatibility study of furosemide & flucloxacillin injections. Br J Pharm Pract 1987 ; 9: 223-226, 236.
1410	Journal	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1415	Journal	Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M. Compatibility of medications with 3-in-1 parenteral nutrition admixtures. JPEN 1999 ; 23: 67-74.
1423	Journal	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hydrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1452	Journal	Muller HJ, Howe K, Frank C, Haker I. Stability of cefazolin, cefotiam, cefuroxime, cefotaxime, ceftriaxone and ceftazidime in normal saline solutions, stored in a new IV container made of Biofine*. Eur Hosp Pharm 2000 ; 6: 17-23.
1611	Journal	Chalmers JR, Bobek MB, Militello MA. Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs. Am J Health-Syst Pharm 2001 ; 58: 504-506.
1656	Journal	Faouzi A, Dine T, Luyckx M, Gressier B, Brunet C, Goudaliez F, Mallevais ML, Cazin M, Cazin JC. Stability and compatibility studies of cefaloridine, cefuroxime and ceftazidime with PVC infusion bags. Pharmazie 1994 ; 49: 425-427.
1674	Journal	Trissel LA, Gilbert DL, Martinez JF. Concentration dependency of vancomycin hydrochloride compatibility with beta-lactam antibiotics during simulated Y-site administration. Hosp Pharm 1998 ; 33: 1515-1522.
1712	Journal	Trissel LA, Saenz CA. Compatibility screening of Precedex during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 230-233.
1713	Journal	Trissel LA, Saenz CA. Compatibility screening of bivalirudin during simulated Y-site administration with other drugs. Int J Pharm Compound 2002 ; 6: 311-315.
1721	Journal	Trissel LA, Williams KY, Baker MB. Compatibility screening of Hextend during simulated Y-site administration with other drugs. Int J Pharm Compound 2001 ; 5: 69-72.
1754	Journal	Trissel LA, Gilbert DL, Wolkin AC. Compatibility of docetaxel with selected drugs during simulated Y-site administration. Int J Pharm Compound 1999 ; 3: 241-244.

1800	Journal	Voytilla KL, Tyler LS, Rusho WJ. Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery. Am J Health-Syst Pharm 2002 ; 59: 853-855.
1803	Journal	Trissel, LA, Saenz CA, Ogundele OB, Ingram D, Baker MB. Compatibility of fenoldopam mesylate with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2003 ; 60: 80-85.
1813	Journal	Gupta VD. Chemical stability of cefuroxime sodium after reconstitution in 0.9% sodium chloride injection and storage in polypropylene syringes for pediatric use. Int J Pharm Compound 2003 ; 7, 4: 310-312.
1888	Journal	Janknegt R, Van den Berg TJ, De Jong M, Oldenhof HGJ, Steenhoek A. Compatibility study of midazolam. Ziekenhuisfarmacie 1986 ; 2: 45-48.
1925	Journal	Trissel LA, Williams KY, Gilbert DL. Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusion solutions. J Am Pharm Assoc 2000 ; 40: 515-519.
1953	Journal	Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004 ; 61: 2289-2293.
1958	Journal	Hecq JD, Schlessler V, Vanbeckbergen D, Jamart J, Galanti L. Effect of freezing, long-term storage and microwave thawing on the stability of cefuroxime sodium in 5% dextrose infusion polyvinyl chloride bags. EJHP Science 2005 ; 11: 23-25.
1972	Journal	Feutry, F., Simon, N., Genay, S., Lannoy, D., Barthelemy, C., Decaudin, B., Labalette, P., Odou, P. Stability of 10 mg/mL cefuroxime solution for intracameral injection in commonly used polypropylene syringes and new ready-to-use cyclic olefin copolymer sterile vials using the LC-UV stability-indicating method. Drug Dev Ind Pharm 2016 ; 42, 1: 166-174.
1982	Journal	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2008	Journal	Hecq JD, Boitquin LP, Vanbeckbergen DF, Jamart J, Galanti LM. Effect of the freezing conditions and microwave thawing power on the stability of cefuroxime in dextrose 5% infusion polyolefin bags at 4°C. Ann Pharmacotherapy 2005 ; 39: 1244-1248.
2087	Journal	Ferreira E, Forest JM, Hildgen P. Compatibility of dimenhydrinate injectable by Y administration. Pharmactuel 2004 ; 37: 17-20.
2090	Journal	Pere H, Chasse V, Forest JM, Hildgen P. Compatibility of injectable pantoprazole in Y-site administration. Pharmactuel 2004 ; 37: 193-196.
2095	Journal	Rodenbach, MP, Hecq JD, Vanbeckbergen D, jamart J, Galanti L. Stability of cefuroxime infusion: the brand-name drug versus a generic product. EJHP Science 2006 ; 12, 2: 32-34.
2109	Journal	Pelletier E, Forest JM, Hildgen P. Compatibilité de la kétamine injectable lors de l'administration en dérivé avec d'autres médicaments usuels. Pharmactuel 2006 ; 39: 71-75.
2231	Journal	de Jongh R, Hens R, Basma V, mouton JW, Tulkens PM, Carryn S. Continuous versus intermittent infusion of temocillin, a directed spectrum penicillin for intensive care patients with nosocomial pneumonia: stability, compatibility, population pharmacokinetic studies and breakpoint selection. J Antimicrob Chemother 2008 ; 61, 2: 382-388.


3012	Journal	Sullivan T, Forrest J.M, Leclair G. Compatibility of Cloxacillin Sodium with Selected Intravenous Drugs During Simulated Y-Site Administration Hosp Pharm 2015 ; 50, 3: 214-220.
3216	Journal	Legris ME, Valiquette ME, Lavoie A, Forest JM, Leclair G. Compatibilité physique par évaluation visuelle du salbutamol injectable lors de son administration en Y. Pharmactuel 2011 ; 44, 1 : 14-18
3380	Journal	Eckle V-S, Heim E, Hahn M, Grasshoff C. Incompatibility of Piritramide with Cephalosporins. Ann Pharmacotherapy 2013 ;47:426-427.
3408	Journal	Tollec S, Touzin K, Pelletier E, Forest J.M. Evaluation visuelle de la compatibilité physique de la naloxone avec d'autres médicaments intraveineux usuels. Pharmactuel 2013 ; 46, 1 : 16-21.
3520	Manufacturer	Cidomycin - Summary of product Characteristics. Sanofi 2011
3549	Manufacturer	Amikacine B Braun - Résumé des caractéristiques du produit. B Braun 2012
3569	Journal	Fleury-Souverain S, Sadeghipour F, Bonnabry P. Development of ready-to-use cefuroxime syringes for use in ophthalmology. EJHP 2014 ;21:34-38
3594	Manufacturer	Metronidazole (Flagyl®) - Summary of Product Characteristics Zentiva 2013
3643	Manufacturer	Gentamicin sulphate (Cidomycin®) - Summary of Product Characteristics Sanofi 2015
3674	Manufacturer	Erythromycin lactobionate - Summary of Product Characteristics PanPharma 2016
3687	Manufacturer	Cefuroxime sodium - Summary of Product Characteristics Stravencon 2013
3766	Journal	Forrest J.M, Hildgen P. Compatibilité de l'acétylcystéine injectable lors de son administration en Y avec d'autres médicaments usuels Pharmactuel 2014 ; 47, 3 : 161-165.
3767	Journal	Legris M.E, Lavoie A, Forrest J.M, Hildgen P. Compatibilité par évaluation visuelle du thiopental injectable lors de son administration en Y avec des médicaments usuels. Pharmactuel 2014 ; 47, 3 : 167-172.
3791	Poster	Sadou Yaye H, Burtet E, Hamel C, Aljhi R, Gard C, Tilleul P. Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures en Y. Apifh Congress, Paris November 2014 2014
3824	Journal	Boudi S, Roy H, Forest JM, Leclair G. Compatibilité physique de l'association amoxicilline-acide clavulanique en injection avec plusieurs autres médicaments lors d'une administration en Y. Pharmactuel 2023 2023;56,3:91-98
3827	Poster	Ghazi I.M, Hamada Y, Nicolau D.P. Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions. ASHP Midyear 2015
3828	Poster	Thabit A.K, Hamada Y, Nicolau D.P. Ceftozolane/tazobactam physical compatibility during simulated Y-site administration. ASHP Midyear 2015
3829	Poster	So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L. Compatibility of isavunazonium sulfate during simulated Y-site administration. ASHP Midyear 2015

3964	Journal	Audet M.A, Forest E, Friciu M, Forest J.M, Leclair G. Compatibilité du citrate de caféine injectable avec plusieurs autres médicaments. Pharmactuel 2017 ; 50,1 : 27-33.
4055	Journal	Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D. Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145	Journal	Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P. Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration. Am J Health-Syst Pharm 2018 ;75,14:1048-1056
4284	Journal	Vercheval C, Streel S, Servais A-C, Fillet M, Van Hees T. Stability of 90 mg/mL cefuroxime sodium solution for administration by continuous infusion. Journal of Chemotherapy 2018 ; 30, 6-8: 371-374.
4319	Journal	Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G. Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs. Hosp Pharm 2020 ; 55, 5: 332-337.
4603	Journal	Vallée M, Barthélémy I, Friciu M, Pelletier E, Forest J.M, Benoit F, Leclair G. Compatibility of Lactated Ringer's Injection With 94 Selected Intravenous Drugs During Simulated Y-site Administration. Hosp Pharm 2021 ; 56, 4: 228-234.
4742	Journal	Macoviciuc M, Nguyen C, Forest J-M, Leclair G. Compatibilité physique de l'acétaminophène injectable avec 102 autres médicaments lors d'une administration en Y. Pharmactuel 2022 ; 55, 4: 247-255.
4801	Journal	Ruiz V, Yuwei Shen Y, Abouelhassan Y, Fouad A, Nicolau D, Kuti J. Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration. Am J Health-Syst Pharm 2024 ;51,1:

Stabilis


































































Cefuroxime sodium



Stability of pharmaceutical preparations













		550 mg Zinacef®	Water for injection >> 10 ml	-30°C		365			2682
		1500 mg Zinacef®	Distilled water >> 30 ml	25°C		24			2683
		1500 mg Zinacef®	polyvinyl alcohol 1.4% Hydroxyethylcellulose Benzalkonium chloride 0.004% Sodium edetate 0.02% NaCl NaOH pH= 4.5-6 Distilled water >> 30 ml	25°C		24			2683
		550 mg Zinacef®	Water for injection >> 10 ml	25°C		24			2682
		550 mg Zinacef®	Water for injection >> 10 ml	2°C		28			2682
		1500 mg Zinacef®	Distilled water >> 30 ml	4°C		14			2683
		1500 mg Zinacef®	polyvinyl alcohol 1.4% Hydroxyethylcellulose Benzalkonium chloride 0.004% Sodium edetate 0.02% NaCl NaOH pH= 4.5-6 Distilled water >> 30 ml	4°C		28			2683

		1500 mg Zinacef®	Hypromellose 0.25% Chlorhexidine acetate 0.0075% NaCl Sodium bicarbonate polysorbate 80 pH= 8-9 Distilled water >> 30 ml	25°C		24			2683
		1500 mg Zinacef®	Hypromellose 0.30% NaCl KCl sodium borate boric acid pH= 8.45 Distilled water >> 30 ml	25°C		24			2683
		1500 mg Zinacef®	Hypromellose 0.25% Chlorhexidine acetate 0.0075% NaCl Sodium bicarbonate polysorbate 80 pH= 8-9 Distilled water >> 30 ml	4°C		28			2683
		1500 mg Zinacef®	Hypromellose 0.30% NaCl KCl sodium borate boric acid pH= 8.45 Distilled water >> 30 ml	4°C		28			2683
		550 mg Zinacef®	Water for injection >> 10 ml	25°C		24			2682
		550 mg Zinacef®	Water for injection >> 10 ml	2°C		21			2682
		1 g ® = Biouroksym®	Water for injection 99 g	4°C		27			3290
		1 g ® = Biouroksym®	Citrate buffer pH 6.25 - 302 mOsmol/L 99 g	4°C		15			3290
		1 g ® = Biouroksym®	Borate Phenylmercuric 0,04% 2,5 g βphenylethylalcohol 0.4 g Citrate buffer pH 6.25 - 302 mOsmol/L 96.1 g	4°C		15			3290
		1 g ® = Biouroksym®	polyvinyl alcohol η = 42 mPas pH 5.75 49 g Borate Phenylmercuric 0.04% 2,5g βphenylethylalcohol 0.4 g Citrate buffer pH 6.05 - 581 mOsmol/L 49.5 g	4°C		18			3290
		1 g ® = Biouroksym®	polyvinyl alcohol η = 42 mPas pH 5.75 49 g Citrate buffer pH 6.05 - 581 mOsmol/L 49.5 g	4°C		18			3290
		5 g ® = Biouroksym®	Water for injection 95 g	4°C		27			3290
		5 g ® = Biouroksym®	Citrate buffer pH 6.28- 160 mOsmol/L 95 g	4°C		15			3290
		5 g ® = Biouroksym®	Borate Phenylmercuric 0,04% 2,5 g βphenylethylalcohol 0.4 g Citrate buffer pH 6.28- 160 mOsmol/L 92.1 g	4°C		15			3290
		5 g ® = Biouroksym®	polyvinyl alcohol η = 42 mPas pH 5.75 47 g Citrate buffer pH 6.25 - 302 mOsmol/L 47.5 g	4°C		27			3290

?		5 g ® = Biouroksym®	polyvinyl alcohol $\eta = 42$ mPas Borate Phenylmercuric 0.04% β phenylethylalcohol 0.4 g Citrate buffer pH 6.25 - 302 mOsmol/L	pH 5.75 2.5g 4°C	46 	30 		3290
---	--	---------------------	--	------------------------	---	--	--	------



Factors which affect stability

					2682
	20°C				3041
	20°C				3290
	4.5 < pH < 7.3				3041




























References

	Type	Publication
2682	Journal	Oldham GB. Formulation and stability of cefuroxime eye-drops. Int J Pharm Pract 1991 ; 1: 19-22.
2683	Journal	Hebron B, Scott H. Shelf life of cefuroxime eye-drops when dispensed in artificial tear preparations. Int J Pharm Pract 1993 ; 23: 163-167.
3041	Journal	Kodym A, Zawisza T, Taberska J, Kukula H. Physicochemical and microbiological properties of eye drops containing cefuroxime. Acta Pol Pharm 2006 ; 63: 293-299.
3290	Journal	Kodym A, Wisniewski A, Kniola D, Olejniczak M. Stability of cefuroxime in 1% and 5% buffered eye drops determined with HPLC method. Acta Pol Pharm 2011 ; 68, 4: 555-564.



Dictionary

 Antibiotic	 injection
 Tradename	 Stability in solutions
 Container	 Molecule
 Concentration	 Temperature
 Storage	 Duration of stability
 Biosimilar	 conflicting data
 References	 Glass
 NaCl 0,9% or Glucose 5%	 Light
 Hour	 Protect from light
 Day	 Not specified
 Sodium chloride 0,9%	 Polyvinyl chloride
 Water for Injection	 Glucose 5%
 Polyethylene	 Polyolefine
 Polypropylen Syringe	 Polyisoprene elastomer
 AT-Closed vial®	 Stability of mixtures
 Solvent	 Compound
 Sodium chloride 0,45%	 NaCl 0,45% Glucose 5%
 None	 Factors which affect stability
 Induces	 Reduced stability
 Micro-waves	 Degradation
 Compatibility	 Compatible
 Chemical instability	 Incompatible
 Unspecified incompatibility	 Immediate precipitation
 Precipitation after 24 hours	 Parenteral nutrition (binary mixture)
 Parenteral nutrition (with lipids)	RL Ringer's lactate solution
 specific solvent	 Immediate turbidity
 Precipitation after 8 hours	 Precipitation after 1 hour
 Route of administration	 Intravenous
 Intravenous infusion	 Intramuscular
 References	 Eye-drops

 Stability of pharmaceutical preparations	 Origine
 excipient	 Medicine bottle for injection
 plastic bottle	 Not specified
 Increase	 Enhanced stability
 Dictionary	